Training in Pharmacometrics and the Therapeutic Application of Nanotechnology

描述(由申请人提供)：本次申请儿科药理学专业临床研究者发展奖(MSCIDA)的主要目的是为帕特里克·A·汤普森博士提供儿科临床药理学方面的综合培训计划，汤普森博士是一名符合董事会资格的儿科医生，也是血液肿瘤学的专科研究员。帕特里克在工程学、数学建模和临床医学方面有着独特的背景。为Thompson博士量身定做的这一综合培训计划是为了1)进一步发展他在药代动力学建模和药代动力学、药效学和药物遗传学相关性方面的能力，2)为他提供设计、实施和分析儿科临床治疗试验的知识和能力，3)让他彻底了解与儿科药物和生物学标签相关的复杂监管问题，以及4)教他进行药理学方面的翻译研究。他的培训将通过贝勒医学院(BCM)儿科药理学研究部(PRRU)进行，并将包括正式参加在美国临床药理学委员会注册的BCM临床药理学奖学金计划。BCM临床药理学奖学金课程涵盖了MSCIDA奖项要求的所有主题。它包括参加BCM，NIH-K30赠款支持的临床科学家培训计划(CSTP)，休斯顿大学药学院的正式课程，以及通过德克萨斯大学和德克萨斯儿童医院的临床轮换。这一奖学金的教学部分还包括在食品和药物管理局与制药行业的外部轮换，以及与PPRU合作站点的基于人口的建模专家的轮换。汤普森博士职业规划的研究部分包括两个项目：1)利用人口建模技术评估重要抗癌药物伊立替康的药代动力学变异性的药物计量学项目；2)表征两种以抗体为靶标的治疗性金纳米颗粒的药理学和生物分布的项目，这两种纳米颗粒在治疗恶性肿瘤或其他疾病过程中具有很好的应用前景。汤普森博士提出的职业发展计划将为实现他成为儿科临床药理学领域领先的临床科学家和教育工作者的长期目标奠定良好的基础。

DESCRIPTION (provided by applicant): The primary aim of this application for the Mentored Specialized Clinical Investigator Development Award (MSCIDA) in Pediatric Pharmacology is to provide a comprehensive training program in pediatric clinical pharmacology for Dr. Patrick A. Thompson, a board-eligible pediatrician and sub-specialty fellow in hematology-oncology. Patrick has a unique background in engineering, mathematical modeling and clinical medicine. This comprehensive training program for Dr. Thompson has been tailored to 1) further develop his capabilities in pharmacokinetic modeling and pharmacokinetic, pharmacodynamic and pharmacogenetic correlations, 2) provide him with the knowledge and ability to design, conduct, and analyze pediatric clinical therapeutics trials, 3) give him a thorough understanding of the complex regulatory issues associated with pediatric labeling of drugs and biology, and 4) teach him to carry out translational research in pharmacology. His training will occur through Baylor College of Medicine's( BCM) Pediatric Pharmacology Research Unit (PRRU) and will include formal enrollment in the BCM Clinical Pharmacology Fellowship Program, which is registered with the American Board of Clinical Pharmacology. The BCM Clinical Pharmacology fellowship program curriculum covers all the topics required by the MSCIDA award. It includes participation in BCM's, NIH-K30 grant-supported Clinical Scientist Training Program (CSTP), formal coursework at the University of Houston College of Pharmacy, and clinical rotations through the University of Texas and Texas Children's Hospital. The didactic component of this fellowship also includes outside rotations at the Food and Drug Administration, with the pharmaceutical industry, and with experts in population-based modeling at a collaborating PPRU site. The research component of Dr. Thompson's career plan includes two projects: 1) a pharmacometric project to evaluate the pharmacokinetic variability of an important anticancer agent, irinotecan, utilizing population modeling techniques; and 2) a project to characterize the pharmacology and biodistribution of two types of therapeutic antibody-targeted gold nanoparticles that have promising applications for the treatment of malignant or other disease processes. The proposed Career Development Plan for Dr. Thompson will provide an excellent foundation for achieving his long-term goal of becoming a leading clinician-scientist and educator in pediatric clinical pharmacology.